Empowered Funds LLC Has $8.87 Million Position in HCA Healthcare, Inc. (NYSE:HCA)

Empowered Funds LLC boosted its position in HCA Healthcare, Inc. (NYSE:HCA) by 10.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,824 shares of the company’s stock after purchasing an additional 2,019 shares during the quarter. Empowered Funds LLC’s holdings in HCA Healthcare were worth $8,870,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of HCA. Bangor Savings Bank raised its stake in HCA Healthcare by 112.5% in the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. MFA Wealth Advisors LLC bought a new position in HCA Healthcare in the second quarter valued at approximately $27,000. Unique Wealth Strategies LLC bought a new position in shares of HCA Healthcare in the 2nd quarter valued at $28,000. GPS Wealth Strategies Group LLC grew its stake in shares of HCA Healthcare by 284.0% during the second quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after buying an additional 71 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of HCA Healthcare during the second quarter worth about $33,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Down 0.7 %

Shares of NYSE:HCA opened at $342.96 on Friday. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. HCA Healthcare, Inc. has a 12-month low of $238.82 and a 12-month high of $417.14. The stock’s 50-day moving average price is $385.11 and its 200-day moving average price is $357.25. The stock has a market capitalization of $86.87 billion, a P/E ratio of 15.40, a price-to-earnings-growth ratio of 1.34 and a beta of 1.68.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Friday, December 13th will be given a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, December 13th. HCA Healthcare’s payout ratio is 11.85%.

Insider Buying and Selling

In other news, EVP Michael S. Cuffe sold 8,358 shares of HCA Healthcare stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the sale, the executive vice president now owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. The trade was a 21.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Erol R. Akdamar sold 2,900 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares of the company’s stock, valued at $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,155 shares of company stock valued at $5,608,990 over the last ninety days. 1.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HCA shares. StockNews.com cut HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $392.00 price target on shares of HCA Healthcare in a research report on Tuesday, October 1st. Wolfe Research raised shares of HCA Healthcare to a “strong-buy” rating in a research report on Thursday, August 29th. TD Cowen lowered their price objective on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. Finally, UBS Group increased their target price on shares of HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $385.00.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.